Survival outcomes for patients with T3N0M0 squamous cell carcinoma of the glottis treated with definitive radiation alone versus chemoradiation. Issue 2 (26th November 2022)

• Record Type: Journal Article
• Authors: Rock, Calvin B.; Hutten, Ryan J.; Weil, Chris R.; Lloyd, Shane; Kerrigan, Kathleen C.; Cannon, Richard B.; Hitchcock, Ying J.
• Is Part Of: Head & neck. Volume 45:Issue 2(2023)
• Page Start: 431
• Page End: 438
• Publication Date: 2022-11-26
• Subjects: chemoradiation -- glottis -- head and neck cancer -- larynx -- oral cancer -- radiation -- survival; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.27255
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: Given the poor lymphatics of the glottis, we evaluated omission of chemotherapy in patients treated definitely for T3N0M0 squamous cell carcinoma (SCC) of the glottis. Methods: We performed survival analysis of patients with T3N0M0 SCC of the glottis identified in the National Cancer Database treated with radiation alone versus chemoradiation. Results: A total of 3785 patients were identified. Patients age ≥70 and those with comorbidities were less likely to receive chemotherapy (odds ratio [OR] 0.30, 95% CI [0.25–0.37] and 0.48 [0.31–0.76], respectively). Five‐year OS was lower in patients treated with radiation versus chemoradiation (33.8% [30.3%–37.2%] vs. 58.0% [55.8%–60.0%]). In patients <70 with no comorbidities this difference persisted (51.0% [44.5%–57.0%] versus 66.7% [64.0%–69.3%]). Conclusion: Overall survival was higher in patients treated with chemoradiation compared to radiation alone, even when controlling for age and comorbidities. Radiotherapy with chemotherapy omission is not appropriate in patients with T3N0M0 SCC of the glottis.